Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 10/20 | 1.00 |
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | HTR3B | O95264 | 2/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31749043 | 0.85 | HRH4 (0.74) | HRH4HTR3AKMT2AKDM4EALDH1A1 | |
| SCHEMBL13801322 | 0.84 | HRH4 (0.72) | HRH4HTR3AKMT2AKDM4EALDH1A1 | |
| SCHEMBL5237102 | 0.84 | HTR3A (0.72) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL31214382 | 0.82 | HTR3A (0.70) | HRH4HTR3AKMT2AKDM4EALDH1A1 | |
| SCHEMBL31214324 | 0.82 | HRH4 (0.70) | HRH4HTR3AKMT2AKDM4EALDH1A1 | |
| SCHEMBL21548076 | 0.82 | HRH4 (0.69) | HRH4HTR3AKMT2AKDM4EALDH1A1 | |
| SCHEMBL5309716 | 0.81 | BCHE (0.71) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL605145 | 0.81 | HRH4 (1.00) | HRH4HTR3APDGFRBFGFR1KDR | |
| SCHEMBL604887 | 0.81 | HRH4 (0.73) | HRH4HTR3APDGFRBFGFR1KDR | |
| SCHEMBL602695 | 0.81 | HRH4 (0.81) | HRH4HTR3APDGFRBFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-7244722-B2 | Amino-substituted 1H-pyrazin-2-ones and 1H-quinoxalin-2-ones | BIOVITRUM AB (SE) | 2007-07-17 | — | — | US | disclosed |
| EP-1534391-B1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| EP-1534391-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | Biovitrum AB (SE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063693-A1 | Compounds | BIOVITRUM AB (SE) | 2004-04-01 | — | — | US | disclosed |
| WO-2004009586-A1 | NOVEL PIPERAZINYL-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF 5-HT2A RECEPTOR-RELATED DISORDERS | BIOVITRUM AB (SE) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063693-A1 | Compounds | HTR1A, HTR1B, HTR2C | HRH4 158/4885HTR3A 11/4885PDGFRB 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.